Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly and Company

https://www.lilly.com/

Latest From Eli Lilly and Company

BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Launches Sales & Earnings

Database In Works To Help Drugmakers Avoid Molecules That Trigger Immune Reactions

Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.

Biologics Research & Development

Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s

Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.

Sales & Earnings Business Strategies

Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety

The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.

Complete Response Letters Safety
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alnara Pharmaceuticals, Inc.
    • ARMO BioSciences, Inc.
    • Applied Molecular Evolution
    • Avid Radiopharmaceuticals, Inc.
    • Bowfin Acquisition Corporation
    • Class AP
    • CoLucid Pharmaceuticals, Inc.
    • Dermira Inc.
    • Disarm Therapeutics, Inc.
    • Hypnion
    • ICOS Corporation
    • ImClone Systems
    • Loxo Oncology, Inc. (LOXO)
    • Protomer Technologies
    • SGX Pharmaceuticals (Structural GenomiX)
    • Valocor Therapeutics, Inc.
UsernamePublicRestriction

Register